
ZBIO
Healthcare · Biotechnology · $1.90B market cap
$28.01+0.37 (+1.3%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -48.0% over 90 days · 30-day revisions 0 up, 2 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 5, 2026 | Before the open | -1.20 | -1.65 | -37.5% |
| Aug 13, 2026 | Before the open | -0.89 | -1.77 | -98.9% |
| May 13, 2026 | Time not confirmed | -1.54 | -1.46 | +5.2% |
| Mar 16, 2026 | Before the open | -1.19 | -1.39 | -16.8% |
| Nov 12, 2025 | Before the open | -0.85 | -1.22 | -43.5% |
| Aug 12, 2025 | Before the open | -1.06 | -1.25 | -17.9% |
| May 15, 2025 | Before the open | -1.15 | -0.80 | +30.4% |
| Feb 26, 2025 | Time not confirmed | -1.02 | -1.26 | -23.7% |
| Nov 12, 2024 | Before the open | -9.30 | -5.02 | +46.0% |
| Aug 22, 2024 | After the close | -1.24 | -2.79 | -125.0% |
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus…